Developer docs
API playgroundTry for free, no card

Search company profiles

Oxular

Full company profile

uuid00026p7

Namestring
Oxular
Legal namestring
Oxular Limited
Websiteurl
oxular.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Oxular Limited is a UK-based clinical-stage biotechnology company founded in 2014 and headquartered in Oxford, United Kingdom, specializing in proprietary ocular gene therapy delivery technology for the treatment of eye disorders, with a particular focus on inflammatory conditions including scleritis. The company's core asset is a domain-specialized gene therapy delivery platform designed to enable targeted biologic and genetic medicine administration to ocular tissues, differentiating it from broader gene therapy developers through ocular-specific engineering. Its vertical segmentation is concentrated in ophthalmology and inflammatory eye disease, with no disclosed commercial products, pricing model, distribution channels, or marketing channels in the source data.

Oxular was financed through three venture rounds totaling approximately $76.7 million between 2016 and 2021, drawing institutional life-sciences investors including Forbion Capital Partners, IP Group, Imperial Innovations, Neomed Management, and V-Bio Ventures. Leadership included Mark Gaffney as Chief Executive Officer, co-founder Tom Cavanagh, and Ronald Yamamoto as Chief Scientific Officer, operating with an 11-50 employee footprint consistent with clinical-stage pipeline development. In January 2025, Oxular was wholly acquired by Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) for an undisclosed sum, with the stated strategic rationale of strengthening Regeneron's ocular gene therapy delivery capabilities. Following the transaction, Oxular operates as a wholly-owned subsidiary of Regeneron, and its independent operating status has ceased.

Short descriptiontext

Oxular Limited is a UK-based clinical-stage biotechnology company developing proprietary ocular gene therapy delivery technology to treat inflammatory eye disorders including scleritis. The company was acquired by Regeneron Pharmaceuticals in January 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ocular gene therapy, ophthalmic drug delivery, eye disorder therapeutics, biologic drug delivery, ocular surface technology
Industry2 codes
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Drug Delivery Technology
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Oxular develops a proprietary ocular gene therapy delivery technology platform designed for treating eye disorders, with specialization in inflammatory eye diseases such as scleritis. The UK-based medical device startup focuses on advancing biologic drug delivery systems targeted at ocular conditions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Ocular Gene Therapy Delivery Platform
Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

In January 2025, Regeneron Pharmaceuticals Inc. acquired UK-based Oxular Limited for an undisclosed sum. The acquisition was specifically aimed at strengthening Regeneron's ocular gene therapy delivery capabilities for treating eye disorders including scleritis. This represents a strategic acquisition to enhance Regeneron's ophthalmology portfolio through Oxular's specialized gene therapy delivery technology.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops gene therapies for ocular diseases, including delivery-focused approaches for retinal disorders. Directly comparable as an ocular gene therapy specialist acquired by a major pharma (Novartis).

TypeDirect peer
Description

Clinical-stage gene therapy company developing novel gene therapy approaches for ocular diseases. Comparable as a competing ocular gene therapy delivery platform targeting inflammatory and retinal indications.

TypeDirect peer
Description

Clinical-stage biotech leveraging AAV-based gene therapy delivery platforms, with active ophthalmology programs. Comparable gene therapy delivery technology targeting eye disorders.

TypeDirect peer
Description

Clinical-stage gene therapy company with a dedicated ophthalmology franchise developing gene therapies for inherited and acquired eye diseases. Comparable ocular gene therapy pipeline and delivery focus.

TypeDirect peer
Description

Specializes in sustained ocular drug delivery technologies, including the Durasert platform for posterior segment diseases. Comparable as an ocular drug delivery specialist targeting inflammatory eye conditions.

TypeDirect peer
Description

Develops suprachoroidal drug delivery technology for ocular diseases including inflammatory conditions. Comparable as an ocular delivery platform addressing similar inflammatory eye indications.

TypeEmerging player
Description

Clinical-stage gene therapy developer focused on rare inherited ophthalmic diseases. Comparable ocular gene therapy pipeline with delivery platform overlap, though narrower indication focus.

TypeBroad incumbent
Description

Pioneer in gene therapy now part of Roche, with approved ophthalmology gene therapy (Luxturna). Comparable as an established ocular gene therapy player with validated delivery platform.

TypeBroad incumbent
Description

Top-tier biopharma with an active ophthalmology franchise (Eylea, aflibercept) and genetic medicines capabilities. Parent of Oxular and strategic acquirer, representing both a peer/partner and an incumbent in ocular therapeutics.

TypeBroad incumbent
Description

Global biopharma with a major ophthalmology franchise (Lucentis, Susvimo) and gene therapy capabilities via Spark. Comparable broad incumbent in ocular therapeutics and genetic medicines.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oxular

Ophthalmic Drug Delivery Technologyoxular.com

Oxular Limited is a UK-based clinical-stage biotechnology company developing proprietary ocular gene therapy delivery technology to treat inflammatory eye disorders including scleritis. The company was acquired by Regeneron Pharmaceuticals in January 2025.

What Oxular does

Oxular Limited is a UK-based clinical-stage biotechnology company founded in 2014 and headquartered in Oxford, United Kingdom, specializing in proprietary ocular gene therapy delivery technology for the treatment of eye disorders, with a particular focus on inflammatory conditions including scleritis. The company's core asset is a domain-specialized gene therapy delivery platform designed to enable targeted biologic and genetic medicine administration to ocular tissues, differentiating it from broader gene therapy developers through ocular-specific engineering. Its vertical segmentation is concentrated in ophthalmology and inflammatory eye disease, with no disclosed commercial products, pricing model, distribution channels, or marketing channels in the source data.

Oxular was financed through three venture rounds totaling approximately $76.7 million between 2016 and 2021, drawing institutional life-sciences investors including Forbion Capital Partners, IP Group, Imperial Innovations, Neomed Management, and V-Bio Ventures. Leadership included Mark Gaffney as Chief Executive Officer, co-founder Tom Cavanagh, and Ronald Yamamoto as Chief Scientific Officer, operating with an 11-50 employee footprint consistent with clinical-stage pipeline development. In January 2025, Oxular was wholly acquired by Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) for an undisclosed sum, with the stated strategic rationale of strengthening Regeneron's ocular gene therapy delivery capabilities. Following the transaction, Oxular operates as a wholly-owned subsidiary of Regeneron, and its independent operating status has ceased.

Oxular firmographics

Firmographics
Name
Oxular
Legal name
Oxular Limited
Website
https://oxular.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
1–10 employees
Short description
Oxular Limited is a UK-based clinical-stage biotechnology company developing proprietary ocular gene therapy delivery technology to treat inflammatory eye disorders including scleritis. The company was acquired by Regeneron Pharmaceuticals in January 2025.
Ownership category
akta.pro rank

Oxular industry classification

Industry
Product category
Ophthalmic Drug Delivery Technology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Ocular gene therapy
  • Ophthalmic drug delivery
  • Eye disorder therapeutics
  • Biologic drug delivery
  • Ocular surface technology

Where Oxular is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Oxular business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Oxular product offering

Product offering

Core offering

Oxular develops a proprietary ocular gene therapy delivery technology platform designed for treating eye disorders, with specialization in inflammatory eye diseases such as scleritis. The UK-based medical device startup focuses on advancing biologic drug delivery systems targeted at ocular conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ocular Gene Therapy Delivery Platform

Companies that use Oxular

Customer profile

Segments1 record

Ideal customer profiles1 record

Oxular technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Oxular partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Regeneron Pharmaceuticals Inc.coreStrategic or Co-development Partner · 1 January 2025In January 2025, Regeneron Pharmaceuticals Inc. acquired UK-based Oxular Limited for an undisclosed sum. The acquisition was specifically aimed at strengthening Regeneron's ocular gene therapy delivery capabilities for treating eye disorders including scleritis. This represents a strategic acquisition to enhance Regeneron's ophthalmology portfolio through Oxular's specialized gene therapy delivery technology.

Recent moves3 records

Expansion highlights3 records

Oxular competitors and assessment

Company assessment

Direct peers

  • Gyroscope Therapeutics: Develops gene therapies for ocular diseases, including delivery-focused approaches for retinal disorders. Directly comparable as an ocular gene therapy specialist acquired by a major pharma (Novartis).
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing novel gene therapy approaches for ocular diseases. Comparable as a competing ocular gene therapy delivery platform targeting inflammatory and retinal indications.
  • Regenxbio: Clinical-stage biotech leveraging AAV-based gene therapy delivery platforms, with active ophthalmology programs. Comparable gene therapy delivery technology targeting eye disorders.
  • MeiraGTx Holdings: Clinical-stage gene therapy company with a dedicated ophthalmology franchise developing gene therapies for inherited and acquired eye diseases. Comparable ocular gene therapy pipeline and delivery focus.
  • EyePoint Pharmaceuticals: Specializes in sustained ocular drug delivery technologies, including the Durasert platform for posterior segment diseases. Comparable as an ocular drug delivery specialist targeting inflammatory eye conditions.
  • Clearside Biomedical: Develops suprachoroidal drug delivery technology for ocular diseases including inflammatory conditions. Comparable as an ocular delivery platform addressing similar inflammatory eye indications.

Emerging players

  • Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy developer focused on rare inherited ophthalmic diseases. Comparable ocular gene therapy pipeline with delivery platform overlap, though narrower indication focus.

Broad incumbents

  • Spark Therapeutics (Roche): Pioneer in gene therapy now part of Roche, with approved ophthalmology gene therapy (Luxturna). Comparable as an established ocular gene therapy player with validated delivery platform.
  • Regeneron Pharmaceuticals: Top-tier biopharma with an active ophthalmology franchise (Eylea, aflibercept) and genetic medicines capabilities. Parent of Oxular and strategic acquirer, representing both a peer/partner and an incumbent in ocular therapeutics.
  • Roche: Global biopharma with a major ophthalmology franchise (Lucentis, Susvimo) and gene therapy capabilities via Spark. Comparable broad incumbent in ocular therapeutics and genetic medicines.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Oxular social profiles

Digital presence

Oxular financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oxular leadership team

Management profile

Number of profiles

Profiles3 records

Oxular funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oxular M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxular

What does Oxular do?

Oxular develops a proprietary ocular gene therapy delivery technology platform designed for treating eye disorders, with specialization in inflammatory eye diseases such as scleritis. The UK-based medical device startup focuses on advancing biologic drug delivery systems targeted at ocular conditions.

Is Oxular a public or private company?

Oxular is a private company. It is classified as corporate owned and is currently acquired.

When was Oxular founded?

Oxular was founded in 2014. It employs 1 to 10 people.

Where is Oxular based?

Oxular is headquartered in Oxford, United Kingdom, in the Europe region.

Who are Oxular's main competitors?

Direct peers on record are Gyroscope Therapeutics, Adverum Biotechnologies, Regenxbio, MeiraGTx Holdings, EyePoint Pharmaceuticals and Clearside Biomedical. Applied Genetic Technologies Corp (AGTC) is listed as an emerging player. Broad incumbents are Spark Therapeutics (Roche), Regeneron Pharmaceuticals and Roche.

Does Oxular have an API?

No public API is recorded for Oxular.

What industry is Oxular in?

Oxular's product category is Ophthalmic Drug Delivery Technology. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCompetitive Analysis: Leading Companies and New Entrants in the Scleritis MarketThe scleritis market is projected to reach $5.95 billion by 2030, growing at a compound annual growth rate of 8.6%, driven by advances in biologic drugs, teleophthalmology, and improved diagnostic technologies. In January 2025, Regeneron Pharmaceuticals Inc. acquired UK-based Oxular Limited for an undisclosed sum to strengthen its ocular gene therapy delivery capabilities for eye disorders including scleritis. In May 2023, India-based Entod Pharmaceuticals launched CYCLOTEARS eye drops globally, using proprietary SEDDS technology to treat inflammatory eye diseases.Eyes On EyecareRegeneron reportedly purchases British biotech OxularRegeneron Pharmaceuticals reportedly acquired Oxular, a UK biotech developing sustained-release retinal treatments. The deal includes OXU-001, a dexamethasone formulation for diabetic macular edema, with a phase 2 trial ongoing. No official details have been released.Seeking AlphaRegeneron expands in eye care with Oxular deal (REGN:NASDAQ)Regeneron Pharmaceuticals acquired Oxular, a U.K.-based biotech focused on ophthalmology, expanding its eye care portfolio. The deal was not formally disclosed, but former Oxular CEO Mark Gaffney confirmed it. Regeneron's Eylea is its primary eye disease therapy.BioSpaceOxular Announces Appointment of Mark Gaffney as Chief Executive OfficerOxular appointed Mark Gaffney as CEO, succeeding Thomas Cavanagh. Gaffney brings over 20 years of biotech leadership, including roles at Vedere Bio and Cyclerion. The company aims to advance its lead asset OXU-001 for diabetic macular edema.PR NewswireOxular appoints Dr. Friedrich Asmus as Chief Medical OfficerOxular Limited, a UK-based retinal therapeutics company, has appointed Dr. Friedrich Asmus as Chief Medical Officer to lead its medical, clinical, and regulatory functions, including the advancement of its lead asset OXU-001 for diabetic macular edema. Dr. Asmus brings over a decade of experience in ophthalmic clinical development, having previously led programs at Bayer Pharma on alfibercept and other therapies, as well as rare-eye disease programs at ProQR Therapeutics and jCyte. The appointment follows Oxular's $37 million financing in March 2021 and coincides with preparations to begin human clinical trials for OXU-001, a sustained-release treatment designed to last up to one year per administration.BusinessCloudBioTech Oxular raises £27m to treat diabetic eye diseaseOxular raised £27 million led by Forbion to fund Phase 2 clinical studies of its 12-month sustained-release dexamethasone treatment for diabetic macular edema. The company plans to progress a retinoblastoma treatment into Phase 2 in 2022.BioWorldOxular advancing once-per-year DME treatment with $37M series BOxular raised $37 million in a series B to advance OXU-001, a long-acting treatment for diabetic macular edema, into phase II development later this year. The funding enables the company to take the drug into phase II.PR NewswireOxular raises $37 millionOxular Limited, a retinal therapeutics company based in Oxford, England, has completed a $37 million (£27 million) financing round led by venture capital firm Forbion, with participation from existing investors IP Group, NeoMed, and V-Bio Ventures. The proceeds will fund Phase 2 clinical trials for OXU-001, a sustained-release dexamethasone formulation for treating diabetic macular edema, with studies commencing later in 2021, as well as accelerate the company's early-stage pipeline including treatments for retinoblastoma, uveal melanoma, and age-related macular degeneration.PR NewswireOxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma TreatmentOxular Limited announced that the U.S. Food and Drug Administration has granted Rare Paediatric Disease and Orphan Drug designations for its proprietary drug OXU-003, intended to treat retinoblastoma. These designations provide regulatory incentives and momentum as the company prepares to enter human clinical trials within the next two years.